Proven efficacy and established safety across 5 indications

NUCALA FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) WITH AN EOSINOPHILIC PHENOTYPE

FOR ADULT PATIENTS

GO TO NUCALA IN COPD
COPD patient Nicholas floating in a pool with a hat and sunglasses

NUCALA FOR EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA)

FOR ADULT PATIENTS

GO TO NUCALA IN EGPA
EGPA patient Meredith in studio holding paintbrush and palette

NUCALA is for the:

  • add-on treatment of patients 6+ with SEA. Not for acute bronchospasm or status asthmaticus.
  • add-on treatment of CRSwNP in patients 18+ with inadequate response to nasal corticosteroids.
  • add-on treatment of adult patients with inadequately controlled COPD and an eosinophilic phenotype. Not for relief of acute bronchospasm.
  • treatment of adult patients with EGPA.
  • treatment of patients aged 12+ with HES for ≥6 months without an identifiable non-hematologic secondary cause.

Hear from your peers about NUCALA

An anti-IL-5 approved for select eosinophil-driven diseases | 8:58

In this NUCALA video series, hear from specialists in immunology, pulmonology, critical care medicine, and otolaryngology.

Watch more expert videos:

NUCALA in patients with SEAkeyboard_arrow_right

NUCALA in patients with CRSwNPkeyboard_arrow_right

Identifying EGPA vs HESkeyboard_arrow_right

Navigate a NUCALA prescription

Enroll a patient todaykeyboard_arrow_right

Review NUCALA patient profiles and dosing information

COPD patient Nicholas playing cards with a female friend

TYPES OF PATIENTS WHO MAY BENEFIT FROM NUCALA

These profiles may remind you of patients in your practice.

REVIEW PATIENT PROFILES

SEAkeyboard_arrow_right

CRSwNPkeyboard_arrow_right

COPD with an eosinophilic phenotypekeyboard_arrow_right

EGPAkeyboard_arrow_right

Get to it

FLEXIBLE ADMINISTRATION OPTIONS FOR ONCE-MONTHLY* NUCALA DOSING

Offer patients fixed dosing independent of weight, and the option of at-home or in-office administration.

*Every 4 weeks.

SEE NUCALA DOSING & ADMINISTRATION INFO

SEAkeyboard_arrow_right

CRSwNPkeyboard_arrow_right

COPD with an eosinophilic phenotypekeyboard_arrow_right

EGPAkeyboard_arrow_right

HESkeyboard_arrow_right

Explore data and patient access details

BLOOD EOSINOPHIL REDUCTION WITH NUCALA

NUCALA reduced blood eosinophils and maintained them within normal levels across indications.1,2 The mechanism of action of mepolizumab has not been definitively established.

Note: Mean normal blood eosinophil levels in a general population of subjects without confounding factors have been reported as 100 cells/µL (range: 34-257) and 107 cells/µL (5th, 95th percentile: 30, 395); levels vary based on age, sex, environmental exposures, and comorbid conditions.1,2

NUCALA HAS BROAD NATIONAL COVERAGE, WITH 95% OF COMMERCIAL PATIENTS COVERED NATIONALLY†

Individual access may vary by geography and plan benefit design.

Formulary status may vary and is subject to change. Formulary coverage does not imply clinical efficacy or safety. This is not a guarantee of partial or full coverage or payment. Consumers may be responsible for varying out-of-pocket costs based on an individual’s plan and its benefit design. Each plan administrator determines actual benefits and out-of-pocket costs per its plan policies. Verify coverage with plan sponsor.

†Pharmacy benefit coverage as of June 2025. “Patients” means covered lives for all approved indications across commercial and employer payer types (excluding Managed Medicaid) as calculated by Managed Markets Insight & Technology (MMIT), LLC.
Source: MMIT, LLC database as of June 2025.
Covered=Any potential for reimbursement from a health plan and may include step edits, prior authorizations, and other restrictions.

Join us for a deeper dive into NUCALA with a live webinar

Choose from live webinars on each indication where a fellow physician guides you through considerations for patient identification, treatment, and safety and efficacy data for NUCALA—including an optional Q&A.

REGISTER FOR A NUCALA WEBINAR

INDICATIONS & IMPORTANT SAFETY INFO

INDICATIONS

IMPORTANT SAFETY INFORMATION

INDICATIONS

NUCALA is indicated for the: 

  • add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. NUCALA is not indicated for the relief of acute bronchospasm.
  • add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma and with an eosinophilic phenotype. NUCALA is not indicated for the relief of acute bronchospasm or status asthmaticus.
  • add-on maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients aged 18 years and older with inadequate response to nasal corticosteroids.
  • treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).
  • treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for greater than or equal to 6 months without an identifiable non-hematologic secondary cause. 

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Known hypersensitivity to mepolizumab or excipients.

 

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Hypersensitivity reactions (eg, anaphylaxis, angioedema, bronchospasm, hypotension, urticaria, rash) have occurred with NUCALA. These reactions generally occur within hours of administration but can have a delayed onset (ie, days). Discontinue if a hypersensitivity reaction occurs.

 

Acute Symptoms of Asthma or COPD or Acute Deteriorating Disease

NUCALA should not be used to treat acute symptoms or acute exacerbations of asthma or COPD, or acute bronchospasm.

 

Opportunistic Infections: Herpes Zoster

Herpes zoster infections have occurred in patients receiving NUCALA. Consider vaccination if medically appropriate.

 

Reduction of Corticosteroid Dosage

Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with NUCALA. Decreases in corticosteroid doses, if appropriate, should be gradual and under the direct supervision of a physician. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

 

Parasitic (Helminth) Infection

Treat patients with pre-existing helminth infections before initiating therapy with NUCALA. If patients become infected while receiving NUCALA and do not respond to anti-helminth treatment, discontinue NUCALA until infection resolves.

 

ADVERSE REACTIONS

Most common adverse reactions (≥5%):

  • Severe asthma trials: headache, injection site reaction, back pain, fatigue
  • CRSwNP trial: oropharyngeal pain, arthralgia
  • COPD trials: back pain, diarrhea, cough
  • EGPA and HES trials (300 mg of NUCALA): most common adverse reactions were similar to severe asthma

Systemic reactions, including hypersensitivity, occurred in clinical trials in patients receiving NUCALA. Manifestations included rash, pruritus, headache, myalgia, flushing, urticaria, erythema, fatigue, hypertension, warm sensation in trunk and neck, cold extremities, dyspnea, stridor, angioedema, and multifocal skin reaction. A majority of systemic reactions were experienced the day of dosing.

 

USE IN SPECIFIC POPULATIONS

The data on pregnancy exposures are insufficient to inform on drug-associated risk. Monoclonal antibodies, such as mepolizumab, are transported across the placenta in a linear fashion as the pregnancy progresses; therefore, potential effects on a fetus are likely to be greater during the second and third trimesters.

 

Please see full Prescribing Information and Patient Information for NUCALA.

PMUS-MPLWCNT250056 June 2025

To report SUSPECTED ADVERSE REACTIONS, contact GSK at gsk.public.reportum.com or 1-888-825-5249 or
FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

References

  1. Felarca AB, Lowell FC. The total eosinophil count in a nonatopic population. J Allergy. 1967;40(1):16-20.
  2. Hartl S, Breyer MK, Burghuber OC, et al. Blood eosinophil count in the general population: typical values and potential confounders. Eur Respir J. 2020;55(5):1901874.